[1]Escudero-Martínez I, Morales-Caba L, Segura T. Atrial fibrillation and stroke: A review and new insights[J]. Trends Cardiovasc Med, 2023, 33(1): 23-29.
[2]Blackshear J L, Odell J A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation[J]. Ann Thorac Surg, 1996, 61(2): 755-759.
[3]Whitlock R P, Belley-Cote E P, Paparella D, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke[J]. N Engl J Med, 2021, 384(22): 2081-2091.
[4]中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618.
[5]January C T, Wann L S, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2): e125-e151.
[6]Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5): 373-498.
[7]van der Endt V H W, Milders J, Penning de Vries B B L, et al. Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation[J]. Europace, 2022, 24(11): 1739-1753.
[8]Pisters R, Lane D A, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey[J]. Chest, 2010, 138(5): 1093-1100.
[9]Granger C B, Alexander J H, McMurray J J, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11): 981-992.
[10]Patel M R, Mahaffey K W, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10): 883-891.
[11]Connolly S J, Ezekowitz M D, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12): 1139-1151.
[12]Giugliano R P, Ruff C T, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22): 2093-2104.
[13]Ruff C T, Giugliano R P, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials[J]. Lancet, 2014, 383(9921): 955-962.
[14]Franciulli M, De Martino G, Librera M, et al. Stand-alone thoracoscopic left atrial appendage closure in nonvalvular atrial fibrillation patients at high bleeding risk[J]. Innovations (Phila), 2020, 15(6): 541-546.
[15]Yoshimoto A, Suematsu Y, Kurahashi K, et al. Early and middle-term results and anticoagulation strategy after left atrial appendage exclusion using an epicardial clip device[J]. Ann Thorac Cardiovasc Surg, 2021, 27(3): 185-190.
[16]Holmes D R, Reddy V Y, Turi Z G, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial[J]. Lancet, 2009, 374(9689): 534-542.
[17]Holmes D R Jr, Kar S, Price M J, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardiol, 2014, 64(1): 1-12.
[18]Reddy V Y, Doshi S K, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial[J]. Circulation, 2013, 127(6): 720-729.
[19]Reddy V Y, Doshi S K, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials[J]. J Am Coll Cardiol, 2017, 70(24): 2964-2975.
[20]Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol, 2020, 75(25): 3122-3135.
[21]Osmancik P, Herman D, Neuzil P, et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation[J]. J Am Coll Cardiol, 2022, 79(1): 1-14.
[22]Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation[J]. J Am Coll Cardiol, 2018, 71(14): 1528-1536.
[23]郑帅, 张海波,李岩,等. 一种新型左心耳闭合装置的初步实验研究[J].中国胸心血管外科临床杂志,2015,22(6):572-577.
|